The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed adoption of Investing Policy/Notice of GM

11 Aug 2015 15:35

RNS Number : 7549V
Fastnet Oil & Gas PLC
11 August 2015
 

 

11 August 2015

 

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

Fundamental change of business, proposed new Investing Policy, proposed name change and Notice of General Meeting

 

Introduction

Fastnet (AIM: FAST, ESM: FOI), announces its intention to undertake a fundamental change in its business pursuant to the AIM Rules and ESM Rules, adopt the Investing Policy and change its name to Fastnet Equity plc (together the "Proposals"). The Proposals are conditional upon Shareholders approving the Investing Policy at the General Meeting.

 

Fastnet's existing oil and gas assets

The Group currently retains oil and gas exploration assets in offshore Morocco, consisting of the Foum Assaka Licence, and offshore Ireland consisting of the Celtic Sea Assets, which is a portfolio of licensing options. The Group's assets are split by geography into two separate subsidiaries being Pathfinder Hydrocarbon Ventures Limited, in respect of the Foum Assaka Licence offshore Morocco, and Fastnet Oil and Gas (Ireland) Limited in respect of the Celtic Sea Assets.

 

Background to the Proposals

The Company was admitted to trading on AIM and the ESM and simultaneously raised £10.0 million in June 2012 with the strategy of identifying early stage exploration opportunities in the Celtic Sea and in Africa. Within a year of being admitted to trading, the Group had established a portfolio of interests in potentially high impact exploration prospects in both onshore and offshore Morocco and offshore Ireland.

In June 2013, Fastnet completed what was at the time the largest ever 3D seismic programme in the Celtic Sea covering 1,910km2 over two option areas, creating the only modern 3D seismic database in the Company's area of interest. In December 2013, Fastnet successfully executed a farm-out of half of its interest in the Foum Assaka Licence, offshore Morocco, to SK Innovation incorporating re-imbursement of back costs, and a US$100 million capped carry on an exploration well which was drilled in April 2014. The SK Innovation farm-out agreement also provided for a carry of Fastnet's working interest in an additional well, provided it was an appraisal well. If an appraisal well was not drilled, the SK Innovation agreement provided for a carry on a future exploration well at SK Innovation's sole discretion. As a result the total cost to Fastnet from acquisition of the Foum Assaka Licence to completion of the FA-1 exploration well, in April 2014, was restricted to US$2.75 million. The FA-1 exploration well drilled was not a commercial success and, accordingly, a subsequent appraisal well was not warranted. Therefore the future carry for Fastnet on the Foum Assaka licence is subject to SK Innovation's election to participate in a second exploration well, which the Board currently considers is unlikely.

As part of the Company's growth strategy, it accelerated progress in relation to its exclusive option (the "Option") to farm into the eight exploration permits comprising the Tendrara Lakbir Petroleum Agreement (the "Tendrara-Lakbir Licence"), the commercial terms of which were improved and extended in July 2014.

In conjunction with the ongoing technical work in Ireland and Morocco, the Company continued in its significant and extensive efforts to farm-out the Group's Celtic Sea Assets and to secure a partner to share drilling costs on the Tendrara-Lakbir Licence.

However the overall worldwide decline in oil prices, which commenced in Q3 2014, has had a materially adverse impact on economic conditions within the oil and gas sector. In particular, it has resulted in a strategic shift in the forward planning of many large oil and gas companies which, the Board believes, has resulted in the delay of decisions and/or changes in strategy regarding farm-in opportunities for exploration assets. As a consequence of the decline in oil prices and despite implementing an extensive marketing process, the Company has been unable to successfully conclude a farm-out of its Celtic Sea Assets to date or of the Tendrara-Lakbir Licence onshore Morocco, prior to the expiry of the Option on 31 December 2014. In addition to the oil price affecting the sector as a whole, the Board believes that Fastnet's offshore Morocco portfolio has become a higher risk / lower potential reward asset as a result of exploration activities and results from other operators in offshore Morocco over the last 24 months.

On 31 May 2015, Fastnet's licensing options in the Celtic Sea relating to the Molly Malone and Mizzen licences expired. In June 2015, Fastnet applied, as part of an open tender process, for licensing options over portions of the original licensing option areas. The award of these licence options remains subject to grant by Minister of State at the Department of Communications, Energy and Natural Resources and it is at the Company's sole discretion to accept the award of these options within 28 days of the award notification. If the Investing Policy is approved by Shareholders, the Company will elect not to accept the award of these options.

The Board undertook a detailed asset review of its oil and gas portfolio in Q4 2014 in light of the rapidly changing economic conditions in the oil and gas sector. The purpose of the asset review was to ensure that Fastnet's corporate strategy to create shareholder value by growing the Company's business and monetise its assets remained on track.

In December 2014, the Board appointed Carol Law as Chief Executive Officer of the Company. This was at a time when the Company's share price was declining rapidly as a consequence, the Board believes, of the decline in oil prices and associated adverse market sentiment regarding the oil and gas sector, particularly for small cap oil and gas exploration companies. The Board announced at that time that its focus was set firmly on restoring and creating shareholder value by implementing its long held strategy of monetising existing assets and continuing to manage prudently its significant cash reserves. The Board also announced its intention to keep all options for the Company under review over the medium term.

Since December 2014, the Company has undergone a comprehensive review of general and administrative costs, which were reduced from December 2014 by more than 40 per cent. to US$1.9 million per year on an annualised basis. These costs have been reduced further in recent weeks and, subject to Shareholder approval of the Investing Policy, the Board intends to make further reductions to such costs to reduce them to below US$0.6 million per annum on an annualised basis.

In the context of the Company's ongoing review, the Board is now of the opinion that the current economic conditions in the oil and gas sector are likely to persist for the medium term. The Board believes that these economic conditions have created an environment in which it is not possible for Fastnet to find partners to carry, with acceptable terms and conditions, some or all of the Company's exploration costs on its oil and gas assets going forward. During the course of 2015, the Company has conducted detailed due diligence on a broad range of merger and acquisition ("M&A") opportunities in the oil and gas sector. However, the Company has not been able to identify an M&A opportunity, in the oil and gas sector, which would create value for Shareholders and therefore be a suitable use of the Company's available cash of US$15.9 million (as at 31 July 2015). During this period, the Board has received certain unsolicited approaches with respect to opportunities outside the oil and gas sector. These have included opportunities in the healthcare sector but, to date, the Company has not pursued these.

In light of the current economic climate within the oil and gas sector, the Board has determined that it is not in the best interests of Shareholders to either pursue M&A opportunities in that sector or to expend further resources on the Company's existing oil and gas assets. In addition, the Company's share price has consistently traded at a discount to the Company's cash balance (equating to 3p per Ordinary Share at 31 July 2015 or 2.8p per Ordinary Share when adjusted for current liabilities) since Q4 2014, implying limited if any value is being attributed to the Group's oil and gas exploration assets.

As a consequence and in order to source opportunities aimed at delivering enhanced value for Shareholders, beyond both the current share price and the current adjusted cash value per Ordinary Share of 2.8p, the Board has elected, subject to Shareholder approval, to undertake a fundamental change in its business pursuant to the AIM Rules and ESM Rules and accordingly to seek Shareholder approval to adopt the Investing Policy, focused on investments in the healthcare sector.

Having undertaken a review, the Board believes that more value can be achieved for Shareholders by utilising the Company's existing listings on AIM and the ESM and applying the Group's corporate infrastructure and cash resources to the proposed Investing Policy. The Board believes that the healthcare industry, particularly the biopharma sector, is experiencing strong momentum and there exist significant M&A and value creation opportunities for both small cap and large cap companies. Furthermore the Board believes that it has access to an international pipeline of such opportunities that could lead to value creation for the Shareholders. The sector is experiencing high activity levels in the UK and also in Ireland, a country where the Company has an existing operating base, with the required management, commercial, fiscal, operational and technical expertise all located in the Irish market.

 

The Board's intentions with the Group's existing assets

Offshore Morocco

Fastnet's running costs in respect of its partnership share in the Foum Assaka Licence are approximately US$25,000 per month based on the approved budget to 31 December 2015. Additionally, should the partnership proceed with drilling a further exploration well and SK Innovation elect not to participate in a second exploration well, the Company would be exposed to the cost and would be required to seek further financing or secure a partner to finance Fastnet's 12.5 per cent paying interest in the Foum Assaka Licence.

The Board is of the view that it is not in Shareholders' interests to maintain this financial exposure given the higher risk / lower potential reward for exploration assets offshore Morocco in the past two years coupled with the prevailing oil price environment. The Board has therefore, subject to the Investing Policy being approved, decided to withdraw from the partnership and surrender its 12.5 per cent. paying interest in the Foum Assaka Licence and will notify the participants in the partnership ("JOA Parties") accordingly. In addition to its pro-rata share for the approved work program and budget items until 31 December 2015, being approximately US$25,000 per month, once notice has been served on the JOA Parties, the Company will also be obligated to pay any cash calls made on the JOA Parties up until 30 September 2015. In addition, the Company will be responsible for all costs associated with respect to filing changes with the other JOA Parties and the relevant government authorities. The Board estimates that the total liabilities in respect of all of the above should not exceed an aggregate sum of US$150,000. 

 

Celtic Sea Assets

It is the Board's intention to terminate all further expenditure on its Celtic Sea portfolio of licensing options. Fastnet will seek to secure a possible disposal or similar transaction of these options before they expire. All costs incurred to date in respect of the Company's Celtic Sea work programmes has been accrued for and is included in the current liabilities figure of US$600,000 (as at 31 July 2015). The Company has other potential liabilities in respect of rental fees and work programmes in respect of certain parts of its Celtic Sea portfolio. The Board estimates that these amounts do not exceed US$150,000 in aggregate.

 

Financial position

As at 31 July 2015 the Company had a cash balance of US$15.9 million and current liabilities of US$0.6 million. During the course of 2015 the Company has undergone a comprehensive review of general and administration costs and has successfully reduced overheads by over 40 per cent since December 2014 to US$1.9 million on an annualised basis. These costs have been reduced even further in recent weeks and, subject to Shareholder approval of the Investing Policy, the Board intends to make further reductions in the annual running costs to reduce it to below US$0.6 million per annum.

 

Investing Policy

If the Investing Policy is approved by Shareholders at the General Meeting, the Company will be required to make an acquisition or acquisitions which will constitute a reverse takeover under the AIM Rules or otherwise implement its Investing Policy within 12 months of the General Meeting, failing which, the Company's Ordinary Shares would then be suspended from trading on AIM and ESM. If the Investing Policy has not been implemented within 18 months of the General Meeting, the admission to trading on AIM and ESM of the Ordinary Shares would be cancelled and the Directors will convene a general meeting of the Shareholders to consider whether to continue seeking investment opportunities or to wind up the Company and distribute any surplus cash back to Shareholders.

The proposed Investing Policy is to acquire companies or businesses in the healthcare sector, particularly those in the biopharma sector. The businesses will typically have attributed to them some or all of the following characteristics:

 

· Strong management team with attractive track records

· An established entity with existing intellectual property

· Markets and products / services with significant commercial opportunities

· Revenue generating or near to medium term revenue generation capabilities

 

The Company will initially focus on opportunities located in Europe but will also consider businesses in other geographical regions. The Directors believe that they have a broad collective range of sources of potential opportunities but also intend to appoint one or more additional directors with the relevant industry experience, subject to the Investing Policy being approved by Shareholders. The Directors will identify and assess potential investment targets and, where they believe further investigation is required, intend to appoint appropriately qualified external professionals to assist. The initial objective of the Directors is to create incremental capital appreciation and any revenue generated by the Company will be applied to further the Investing Policy or will be used in the day to day management of the Company. Dividends may be declared at some future date depending on the financial position of the Company and the availability of distributable accounting profits.

 

The Directors intend that the Company takes an equity interest in a proposed investment which is likely to be a majority position to 100 per cent. ownership. The Company's financial resources are likely to be invested in potentially one or more investments in a single transaction which will be deemed to be a reverse takeover pursuant to Rule 14 of the AIM Rules and ESM Rules, in which case the approval of the Shareholders will be required. Proposed investments may be made in quoted or unquoted securities in companies or partnerships at any stage of development.

 

Proposed changes to the Board

Subject to the approval of the Investing Policy by Shareholders at the forthcoming GM, the Company will become an Investing Company. Based on the decision by the Board to change the focus of the Company from the oil and gas sector to unrelated sectors, Carol Law will resign as a Director and employee upon approval of the Investing Policy at the GM but will continue as a consultant to the Company as she serves out her three month contracted notice period.

It is expected that further changes will be made to the Board, with the appointment of parties with the appropriate knowledge and expertise base to make investments in the healthcare and/or biopharma industry sectors. Details of any such further changes will be announced in due course.

 

Change of Name

In line with the Company's proposed fundamental change of business the Board proposes that the name of the Company be changed to Fastnet Equity plc. The change of name requires the approval of the Shareholders.

 

Change of Registered Office

The Company's registered office has been changed to Ivybridge House, 1 Adam Street, London WC2N 6LE.

 

General Meeting

The General Meeting has been convened for 2pm on 28 August 2015 to be held at the Conrad London St James, 22-28 Broadway, London SW1H 0BH.

 

Defined terms in this announcement have the same meaning as given to them in the circular to Shareholders dated 11 August 2015, unless otherwise stated, and which is available on the Company's website, www.fastnetoilandgas.com.

Ends

For further information please contact:

Fastnet Oil & Gas plc

+353 (1) 644 0007

Cathal Friel, Non-Executive Chairman

Shore Capital

+44 (0) 20 7408 4090

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

Camarco

+44 (0) 20 3757 4980

Billy Clegg, Georgia Mann

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFMGMRDMFGKZM
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.